NASDAQ: BBNXBeta Bionics Inc Stock
$14.53-0.16 (-1.09%)
Updated Jun 12, 2026
BBNX Price
$14.53
Fair Value Price
N/A
Market Cap
$647.48M
52 Week Low
$8.80
52 Week High
$32.71
P/E
-9.69x
P/B
2.39x
P/S
4.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$110.24M
Earnings
-$66.44M
Gross Margin
57.2%
Operating Margin
-60.27%
Profit Margin
-60.3%
Debt to Equity
0.12
Operating Cash Flow
-$55M
Beta
1.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BBNX Overview
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BBNX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
BBNX
Ranked#77 of 94
Ranked#77 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.51 | A | |
| $37.14 | A | |
| $26.31 | A |
Be the first to know about important BBNX news, forecast changes, insider trades & much more!
BBNX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BBNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BBNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BBNX is good value based on its book value relative to its share price (2.39x), compared to the US Medical Devices industry average (2.98x)
P/B vs Industry Valuation
BBNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BBNX due diligence checks available for Premium users.
Valuation
BBNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.69x
Industry
20.73x
Market
14.15x
BBNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.39x
Industry
2.98x
BBNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BBNX's financial health
Profit margin
Revenue
$27.6M
Net Income
-$21.9M
Profit Margin
-79.3%
BBNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BBNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$304.4M
Liabilities
$33.2M
Debt to equity
0.12
BBNX's short-term assets ($247.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBNX's short-term assets ($247.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.8M
Investing
$21.8M
Financing
$623.0k
BBNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BBNX vs Medical Device Stocks
Beta Bionics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.